Please search for your last name

Mayo Clinic
Radiology
The research group of Clifford R. Jack Jr., M.D., is engaged in brain imaging research in cognitive aging and Alzheimer's disease and related disorders. The group develops image-processing algorithms for quantitatively measuring the information obtained from brain imaging. Specific goals are to understand how various imaging measures relate to neuropathology, cognitive, behavior and specific phenotypic abnormalities. All modern brain imaging modalities (amyloid PET, FDG PET, tau PET, anatomic MRI, diffusion imaging, perfusion imaging, task free functional MRI, and quantitative susceptibility mapping) are used along with clinical, psychometric, genetic and neuropathologic information. The group also serves as the MR center for large multi-site observational and interventional studies including ADNI, DIAN, ARIC, A4, A345, SCAN and the Jackson Heart Study.
Lancaster University
STOR-i
Holly Jackson is a PhD student within statistics and operational research at Lancaster university. Her research focuses on investigating novel methodologies in rare disease clinical trials. She completed her MMath degree from the university of Nottingham in 2017 and completed her MRes in statistics and operational research at Lancaster university in 2018. In addition, she completed a 12-month Roche Internship for Scientific Exchange, where she performed exploratory analysis on Parkinson’s disease data. Outside of work, Holly enjoys playing and watching both rugby and football, hiking and reading.
Alector, Inc.
Alector
Sam Jackson, MD, MBA, is the Chief Medical Officer of Alector where he manages a team developing therapies targeting the immune system in an effort to treat neurodegenerative diseases and cancer.
CognitionMetrics, LLC and Albert Einstein College of Medicine
Psychiatry and Behavioral Sciences
Judith Jaeger is neuropsychologist and pharmaceutical executive with more than 30 years’ experience in clinical and experimental neuropsychology and psychopathology. She is Clinical Professor of Psychiatry and Behavioral Science at Albert Einstein College of Medicine, New York as well as President and Principal Scientist at CognitionMetrics, LLC in Wilmington, Delaware, USA. Previously she was Vice President for Clinical Trials at Cogstate, Inc. and Director of Clinical Development at AstraZeneca Pharmaceuticals where she served as company-wide cognition expert for programs in Alzheimer’s disease, ADHD, schizophrenia, bipolar disorder and oncology. Prof. Jaeger’s pharmaceutical industry work has included Phase 0 experimental medicine studies that she has initiated, as well as innovative (Phase Ib/IIa) and conventional (Phase II) PoP/PoC studies as well as pivotal (Phase III) and post-marketing studies. Her global regulatory experience includes speaking before regulatory bodies including the PMDA (Japanese regulatory authories) and with FDA including at an Advisory Committee. She has consulted to clinical teams in 15 of the top 25 pharmaceutical companies in all phases of development on a range of CNS and non-CNS (safety) indications. Professor Jaeger is known for her research on measurement of cognition across a range of central nervous system diseases, with particular attention to measurement of change over time in clinical trials. She has also studied cognitive impairments and their association with disability in psychiatric disorders, including schizophrenia, bipolar and major depressive disorder. She has over 70 peer-reviewed publications, one edited book, seven book chapters and more than 200 published abstracts, conference presentations and invited lectures.
no photo
Roche Innovation Center Basel
Roche Pharma Research and Early Development, Pharmaceutical Sciences
University of California, Berkeley
Helen Wills Neuroscience Institute
Dr. William Jagust joined the faculty of the University of California, Davis in 1986, where he established the UC Davis Alzheimer’s Disease Center and served as Chair of the Department of Neurology from 1998-2004. He moved to the University of California, Berkeley in 2004 where he is a Professor of Public Health and Neuroscience, and a Faculty Senior Scientist at Lawrence Berkeley National Laboratory. Dr. Jagust’s career has been focused on understanding the aging brain, and particularly the borderland between normal cognitive aging and Alzheimer’s disease. His laboratory has pioneered in the use of multimodal imaging to understand brain aging and Alzheimer’s disease, employing positron emission tomography (PET) to measure -amyloid and tau proteins in the brain, and magnetic resonance imaging (MRI) to investigate how these protein aggregates affect neural function and brain structure. He has served on editorial boards of major journals, advisory boards to the National Institute on Aging, and he currently heads the PET core of the Alzheimer’s Disease Neuroimaging Initiative, a 60-center multisite study of imaging in AD. He is a recipient of the 2013 Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Diseases.
no photo
School of Pharmaceutical Education and Research, Jamia Hamdard
Pharmaceutics
Dhara Jain is a PhD research scholar working in Nanoformulation and Research Laboratory, Jamia Hamdard under the supervision of Prof. Farhan J Ahmad. She is the Principal Investigator of project titled "Targeted delivery of anti-Alzheimer drugs loaded lipid nanoparticles to the brain" funded by Department of Science & Technology, Government of India, New Delhi. Her research findings have been published in reputed journals such as Journal of Controlled Release and Acta Biomaterialia
Aarhus University
Department of Biomedicine
I completed professional studies in Clinical Medicine and obtained PhD in Neuroscience. During my academic tenures, I have provided scientific leadership and project management in research studies applied to age related neurological diseases, in particular Alzheimer disease (AD) and Parkinson disease (PD). In close collaboration with several international teams- often involving academic and clinical (pathologists, oncologists, and neurologists) researchers, my research work has contributed to novel insights into the pathogenic mechanism in brain pathologies, in particular disrupted regulation of mRNA translation (via eEF2 kinase) and impaired redox regulation (e.g., Nrf2 anti-oxidant response). These studies encompass cellular and animal models, rigorous histopathological analyses of human post-mortem tissue specimen, and through validation in patient-derived microarray gene expression datasets.
no photo
Lund University
Clinical Memory Research Unit, Department of Clinical Sciences
no photo
Korea National Sport University
Training for Health Care and Management
no photo
Ajou university school of medicine
Department of Biomedical Sciences
no photo
Universitat de Barcelona
Farmacologia, Toxicologia i Química Terapèutica
Columbia University Medical Center
Department of Psychiatry, Division of Experimental Therapeutics
Dr. Javitt's research focuses on brain mechanisms of psychosis and other severe psychiatric disorders, with special emphasis on the role of brain glutamate systems and N-methyl-D-aspartate (NMDA)-type glutamate receptors in health and disease. Dr. Javitt was among the first to demonstrate a link between NMDA dysfunction and schizophrenia, and has been instrumental in developing glutamatergic theories of schizophrenia over the past 20 years. He was also among the first to test new classes of NMDA-based treatments for schizophrenia, including glycine, D-serine and glycine transport inhibitors, and has more recently initiated studies of NMDA receptor antagonists, such as ketamine and high-dose D-cycloserine in treatment of depression, and of brain stimulation methods, including transcranial direct current stimulation (tDCS) as an adjunct to cognitive remediation. Dr. Javitt has published over 250 articles on topics relating to normal and abnormal brain function in serious psychiatric illness. He has received awards for his research from numerous organizations, including the American Psychiatric Association, American College of Neuropsychopharmacology, Society for Biological Psychiatry, American College of Psychiatrists and the Child Welfare League of America. His work has also been featured in the PBS special "Prisoners of the Brain", and Scientific American. His research is supported by the National Institute for Mental Health, the National Institute on Drug Abuse, the Stanley Medical Research Institute, and other philanthropic organizations. He currently serves as associate editor of Schizophrenia Bulletin, and as an editorial board member for several prestigious journals including Schizophrenia Research and the American Journal of Psychiatry. He is a former chair of the NIMH NPAS study section. He is a Fellow of the American College of Neuropsychopharmacology, an advisory board member for the Brain and Behavior Research Foundation and a standing member of the Institute of Medicine Neuro Forum.
Aarhus University
Biomedicine
PhD student at DANDRITE, Aarhus University, Denmark, with a research focus on synucleinopathies, mainly using various antibody-based staining techniques and automated image quantification across a range of model types and human tissue.
University of Cologne
Dept of Psychiatry
Frank Jessen received his MD degree from the University of Saarland in 1995. After residencies in neuropathology at the University of Duesseldorf, and neurology and psychiatry at the University of Bonn, he was board certified as a psychiatrist and psychotherapist in 2002. He served from 2002-2010 as a consultant psychiatrist and head of clinical Alzheimer’s disease research at the Department of Psychiatry, University of Bonn. In 2010, he was appointed Professor of clinical dementia research and deputy director of the Department of Psychiatry, University of Bonn. In 2015, he was appointed as a professor of psychiatry and psychotherapy and director of the Department of Psychiatry, University of Cologne. Since 2010, he is an associate researcher at the German Center of Neurogenerative Disorders (DZNE). Frank Jessen’s research focusses on early diagnosis and clinical trials in Alzheimer’s disease with expertise in neuropsychology, neuroimaging, epidemiology and genetics.
Boston University
Pharmacology
Dr. Lulu Jiang is a Research Assistant Professor in the Pharmacology & Experimental Therapeutics department at the Boston University School of Medicine. Dr. Jiang’s PhD training was from the National Institute of Environmental Health Sciences (NIEHS) in USA and MD training from Shandong University in China. She was a Postdoc Fellow in the Laboratory of Neurodegeneration mentored by Dr. Benjamin Wolozin. Her previous work demonstrated that propagated tau oligomers (but not tau fibrils) induce pathological changes in RNA metabolism and neurodegeneration. Upon that, Dr. Jiang developed an optogenetic system for controlling tau aggregation, which brought in a seminal discovery that tau oligomerization drives the accumulation of RNA binding protein HNRNPA2B1 and N6-methyladenosine modified transcripts in the aggregated tau complex. Dr. Jiang has also lead on the generation of human 3D iPSC M/AstAD based models of AD for the exploration of molecular mechanism and drug screening. Her research interests include: 1) Protein-Protein and Protein-RNA interactions in AD and related dementia; 2) Molecular mechanism of Tau prion-like propagation in Braak stages of AD; 3) Neuron-glia interactions in pathogenesis of AD and PD; 4) iPSC-induced 3D brain organoid models of neurodegenerative diseases and precision medicine; 5) Development of novel therapeutics for neurodegenerative diseases.
no photo
The Hong Kong University of Science and Technology
Division of Life Science
no photo
Dong-A University School of Medicine
Neurology
no photo
Deutsches Zentrum für Neurodegenerative Erkrankungen
Neuroproteomics